J Jassem

Summary

Country: Poland

Publications

  1. doi Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Breast 21:89-94. 2012
  2. pmc Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004
    Elzbieta Senkus-Konefka
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Breast Cancer Res 6:148-52. 2004
  3. ncbi A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life
    Jacek Jassem
    Medical University of Gdansk, 7 Debinki Street, 80 211, Gdansk, Poland
    Lung Cancer 35:73-9. 2002
  4. ncbi A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Ann Oncol 12:1375-81. 2001
  5. ncbi P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Cancer 100:1951-60. 2004
  6. ncbi Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Lancet Oncol 2:335-42. 2001
  7. ncbi The role of radiotherapy in lung cancer: where is the evidence?
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Radiother Oncol 83:203-13. 2007
  8. ncbi Cancer clinical trials in Central and Eastern Europe: historical review
    Jacek Jassem
    Deptartment of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Crit Rev Oncol Hematol 42:157-61. 2002
  9. doi Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial
    Jacek Jassem
    Dept of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Onkologie 32:468-72. 2009
  10. ncbi Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Ann Oncol 14:1634-9. 2003

Detail Information

Publications109 found, 100 shown here

  1. doi Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Breast 21:89-94. 2012
    ..Here we report the efficacy and safety of these treatments in a prespecified subset of patients whose disease relapsed within 12 months...
  2. pmc Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004
    Elzbieta Senkus-Konefka
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Breast Cancer Res 6:148-52. 2004
    ..The present article provides a brief description of the most important conference presentations on molecular biology, epidemiology, prevention, pathology, diagnosis and treatment at all stages of breast cancer...
  3. ncbi A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life
    Jacek Jassem
    Medical University of Gdansk, 7 Debinki Street, 80 211, Gdansk, Poland
    Lung Cancer 35:73-9. 2002
    ..However, the high frequency of myelotoxicity-related gemcitabine omissions on day 15 of the cycle indicates that modification of the schedule should be considered in standard care...
  4. ncbi A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Ann Oncol 12:1375-81. 2001
    ..intravenous (i.v.) vinorelbine was designed to determine the efficacy and safety of oral vinorelbine with an intrapatient dose escalation in previously untreated patients with advanced non-small-cell lung cancer (NSCLC)...
  5. ncbi P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Cancer 100:1951-60. 2004
    ....
  6. ncbi Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Lancet Oncol 2:335-42. 2001
    ..The role of new agents such as taxanes, vinorelbine, gemcitabine, and topoisomerase inhibitors in combined modality therapy of non-small-cell lung cancer warrants further clinical investigation...
  7. ncbi The role of radiotherapy in lung cancer: where is the evidence?
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Radiother Oncol 83:203-13. 2007
    ..In small cell lung cancer, routine applications of radiotherapy include chest radiotherapy in limited disease and prophylactic cranial irradiation in complete responders to chemotherapy, each increasing survival by about 5%...
  8. ncbi Cancer clinical trials in Central and Eastern Europe: historical review
    Jacek Jassem
    Deptartment of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Crit Rev Oncol Hematol 42:157-61. 2002
    ..Most recently another regional cooperative group has been created: the Central European Cooperative Oncology Group (CECOG), whose main objectives are to conduct phase III studies on new chemotherapy combinations...
  9. doi Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial
    Jacek Jassem
    Dept of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Onkologie 32:468-72. 2009
    ....
  10. ncbi Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Ann Oncol 14:1634-9. 2003
    ..v. and oral vinorelbine in combination with cisplatin was designed to determine the response rate, safety profile, progression-free survival, overall survival and quality of life (QoL) in advanced non-small-cell lung cancer (NSCLC)...
  11. ncbi Combined chemotherapy and radiotherapy in inoperable non-small cell lung cancer
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki St, 80 211 Gdansk, Poland
    Lung Cancer 38:S43-6. 2002
    ..The value of new agents (taxanes, vinorelbine, gemcitabine and topoisomerase inhibitors) in combined modality therapy of NSCLC seems to be promising, but warrants further clinical evaluation...
  12. ncbi [Systemic treatment of non-small cell lung cancer--recommendations based on the results of reliable clinical trials]
    Jacek Jassem
    Katedra i Klinika Onkologii i Radioterapii, Akademia Medyczna w Gdansku, Gdansk
    Pneumonol Alergol Pol 76:44-52. 2008
    ..As many new studies have been published since, it was necessary to update this document. We present here a consensus statement on this topic, prepared by a panel of experts in oncology, thoracic surgery, pathology and pneumonology...
  13. ncbi Chemoradiotherapy of non-small cell lung cancer
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Expert Rev Anticancer Ther 2:402-7. 2002
    ..This review provides the rationale for this strategy and presents the results of major Phase III studies. Discussed are advantages of chemoradiation, its limitations in clinical practice and prospects for the future...
  14. doi Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma
    Jacek Jassem
    Radiotherapy and Oncology, Medical University of Gdansk, Debinki 7 St, Gdansk, Poland
    J Clin Oncol 26:1698-704. 2008
    ..Secondary end points included response rate, progression-free survival (PFS), time to tumor progression (TTP), time to treatment failure (TTF), and toxicity...
  15. ncbi Combined modality treatment with chemotherapy and radiation in locally advanced non-small cell lung cancer
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki St, 80 211, Gdansk, Poland
    Lung Cancer 34:S181-3. 2001
    ..Presented are rationale for the use of this strategy, methods of combining drugs and radiation and results of major phase III trials...
  16. ncbi Radiotherapy for non-small cell lung cancer
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki St, 80 211, Gdansk, Poland
    Lung Cancer 34:S177-80. 2001
    ..The following applications of radiotherapy are addressed: definitive treatment in localized inoperable disease, radiotherapy as an adjunct to surgery (preoperative and postoperative), and palliative chest irradiation...
  17. ncbi Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial
    J Jassem
    Department of Oncology and Radiotherapy, Medical University, Gdansk, Poland
    J Clin Oncol 19:1707-15. 2001
    ..This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line therapy for women with metastatic breast cancer...
  18. ncbi Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?
    B Jereczek-Fossa
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    J Cancer Res Clin Oncol 124:106-12. 1998
    ..06). These findings suggest a relationship between chemotherapy-induced leukopenia and tumour response in SCLC...
  19. ncbi Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer
    E Jassem
    Department of Allergology, Medical Univerity of Gdansk, Gdansk, Poland
    Biomarkers 11:262-9. 2006
    ..005). S-100 protein expression in tumour cells seems to be an independent predictor of poor prognosis in NSCLC patients...
  20. ncbi Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients
    Dorota Dworakowska
    Department of Internal Medicine, Endocrinology and Hemostatic Disorders, Medical University of Gdansk, Poland
    Oncology 67:60-6. 2004
    ..The study group included 195 NSCLC consecutive patients from one institution who underwent curative pulmonary resection between 1994 and 1999...
  21. ncbi Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer
    K Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki Street, 80 211 Gdansk, Poland
    Int J Gynecol Cancer 16:1152-6. 2006
    ..In conclusion, MIC regimen provides satisfactory efficacy with acceptable toxicity in advanced cervical cancer patients. Better response is seen in lesions outside of the previously irradiated area...
  22. ncbi Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy
    B Jereczek-Fossa
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Int J Radiat Oncol Biol Phys 48:405-13. 2000
    ....
  23. ncbi Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification
    J Jassem
    Departments of Oncology and Radiotherapy, Thoracic Surgery, Pneumonology, and Pathology, Medical University of Gdansk, Poland
    J Thorac Cardiovasc Surg 119:1141-6. 2000
    ..Prognostic relevance of the current TNM stage grouping for lung cancer is still a matter of debate...
  24. ncbi MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)
    Dorota Dworakowska
    Department of Internal Medicine, Endocrinology and Haemostatic Disorders, Medical University of Gdansk, Gdansk, Poland
    Lung Cancer 43:285-95. 2004
    ..01 for both comparisons). Our results suggest that MDM2 gene amplification analysis provides additional prognostic information in surgically treated NSCLC patients...
  25. ncbi Rectal doses in intracavitary brachytherapy of gynecological malignancies: comparison of two dosimetric methods
    K Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland
    Radiother Oncol 58:37-41. 2001
    ..CONCLUSION: The rectal point dose determined with the use of rectal wire marker may be underestimated, therefore this method should be discouraged in gynecological brachytherapy...
  26. ncbi Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression
    D Dworakowska
    Department of Internal Medicine, Endocrinology and Haemostatic Disorders, Medical University of Gdansk, Gdansk, Poland
    J Cancer Res Clin Oncol 131:617-23. 2005
    ....
  27. ncbi Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer
    D Dworakowska
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki St 80 211, Gdansk, Poland
    Lung Cancer 35:35-41. 2002
    ..These results suggest the lack of prognostic relevance of p53 and PCNA expression in surgically treated NSCLC patients...
  28. ncbi Types and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patients
    E Jassem
    Department of Pneumonology, Medical University of Gdansk, Debinki 7, 80 211, Gdansk, Poland
    Lung Cancer 34:S47-51. 2001
    ..This homogeneity, together with our earlier findings, may confirm the impact of ethnic and geographical factors on the mutational profile of p53 gene in NSCLC...
  29. ncbi Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance
    E Jassem
    Department of Pneumonology, , 7 Debinki St, 80-211, , Poland
    Lung Cancer 31:17-23. 2001
    ..Median survival in SCLC patients with and without antibodies was 42 and 39 weeks, respectively (log rank, P=0.81). These results indicate the lack of clinical relevance of serum p53 antibodies in SCLC...
  30. ncbi A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer
    Andrzej Badzio
    Department of Oncology and Radiotherapy, Medical University of Gdansk, ul Debinki 7, 80 211 Gdansk, Poland
    Eur J Cardiothorac Surg 26:183-8. 2004
    ..High incidence of local relapses after chemotherapy in limited-stage SCLC led to reassessment of the role of local treatment in the multimodality management of this tumor...
  31. ncbi Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism
    Amelia Szymanowska
    Department of Allergology, Medical University of Gdansk, Gdansk, Poland
    Lung Cancer 52:9-14. 2006
    ..Additionally, the correlation between Pro72 and somatic TP53 mutations suggests that Pro72 allele carriers may be predisposed to tumour development along a p53 associated form of NSCLC, a finding that warrants further investigations...
  32. doi Intergroup Exemestane Study mature analysis: overall survival data
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Anticancer Drugs 19:S3-7. 2008
    ..Data from IES concur with the findings of other studies with AIs that support the rationale of switching from tamoxifen to an AI after 2-3 years of tamoxifen in postmenopausal women who remain disease-free...
  33. ncbi Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate
    R Zaucha
    Department of Oncology and Radiotherapy, Medical University of Gdansk, ul Debinki 7, 80 211 Gdansk, Poland
    Breast 13:321-4. 2004
    ..Despite bulky visceral disease and chemoresistance, hormonal treatment with MPA resulted in a spectacular and long-lasting response...
  34. ncbi Chemotherapy of advanced non-small cell lung cancer
    J Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Ann Oncol 10:77-82. 1999
    ..Despite recent developments, treatment outcomes in advanced NSCLC remain far from satisfactory, and new effective means are desperately needed if more patients are to enjoy the prospects of long-term survival...
  35. ncbi Expression of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC)--a preliminary report
    R Dziadziuszko
    Department of Oncology, Medical University, , Poland
    Folia Histochem Cytobiol 39:100-1. 2001
    ..The expression of VEGF and FLK-1 in NSCLC cells was confirmed in this study. The relation to clinical variables and survival will be further assessed in a larger group of patients...
  36. doi Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung
    Marcin Skrzypski
    University of Gdansk, Gdansk, Poland
    Clin Cancer Res 14:4794-9. 2008
    ..Current staging methods are imprecise indications of prognosis, but high-risk patients can be identified by gene expression profiling and considered for adjuvant therapy...
  37. ncbi The role of pemetrexed combined with targeted agents for non-small cell lung cancer
    Krzysztof Konopa
    Dept of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Curr Drug Targets 11:2-11. 2010
    ..Combinations of pemetrexed with other targeted agents, such as mTOR inhibitors and compounds targeting proteasome are still at early stages of development...
  38. pmc A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)
    E Senkus-Konefka
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Debinki 7, 80 211 Gdansk, Poland
    Br J Cancer 92:1038-45. 2005
    ..The improved overall survival and treatment convenience of 2-fraction schedule suggest its usefulness in the routine management of symptomatic inoperable NSCLC...
  39. ncbi Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
    R Dziadziuszko
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Ann Oncol 23:x193-6. 2012
    ....
  40. ncbi Complications of breast-cancer radiotherapy
    E Senkus-Konefka
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Clin Oncol (R Coll Radiol) 18:229-35. 2006
    ..In this paper, we review the contemporary knowledge on the toxicity of breast-cancer radiotherapy and discuss possible preventive measures...
  41. ncbi [Platinum-based chemotherapy in renal transplant recipients with malignancies: a case report and review of literature]
    J Wojcik
    Kliniki Onkologii i Radioterapii AM
    Pol Merkur Lekarski 5:145-6. 1998
    ..The safety of platinum-based chemotherapy in renal transplant recipients is discussed with reference to the literature data...
  42. ncbi Penile metastases from urogenital primaries
    K Matuszewska
    Department of Oncology and Radiotherapy Medical University of Gdansk, Gdansk, 80 952 Poland
    Neoplasma 49:346-8. 2002
    ..Nevertheless, the prognosis is poor, because the disease is already disseminated and in most cases other metastases will occur soon...
  43. ncbi EPR/alanine dosimetry in LDR brachytherapy--a feasibility study
    Katarzyna Schultka
    Department of Physics and Biophysics, Medical University of Gdansk, Debinki 1, 80 211 Gdansk, Poland
    Radiat Prot Dosimetry 120:171-5. 2006
    ....
  44. doi Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer
    Dorota Dworakowska
    Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Poland
    Lung Cancer 66:127-33. 2009
    ..04). This study demonstrates that joint analysis of several factors involved in apoptosis, proliferation and cell cycle regulation, but not AI alone, might provide additional prognostic information in NSCLC patients...
  45. ncbi Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomised phase III study (EORTC 10974/22002, LAMANOMA)--why did this study fail?
    Marcin Sinacki
    Department of Oncology and Radiotherapy, Medical University of Gdansk, ul Debinki, 7, 80 211 Gdansk, Poland
    Eur J Cancer 41:2787-8. 2005
  46. ncbi Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients
    Witold Rzyman
    Department of Thoracic Surgery, Medical University of Gdansk, Gdansk, Poland
    Ann Thorac Surg 82:237-42. 2006
    ....
  47. ncbi Intraocular malignant teratoid medulloepithelioma in an adult: clinicopathological case report and review of the literature
    Katarzyna Sosinska-Mielcarek
    Department of Oncology and Radiotherapy, Medical University of Gedansk, Gedansk, Poland
    Acta Ophthalmol Scand 84:259-62. 2006
    ..To report a case of intraocular medulloepithelioma, an embryonal tumour with extremely rare presentation in adults...
  48. ncbi (CA)n microsatellite polymorphism of ERBB-1 in breast cancer
    Marzena Wełnicka-Jaśkiewicz
    Department of Oncology and Radiotherapy, Medical University of Gdansk, ul Debinki 7, 80 211 Gdansk, Poland
    Eur J Cancer 42:1698-701. 2006
    ..The clinical relevance of ERBB-1 microsatellite polymorphism in breast cancer remains to be established...
  49. ncbi BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland
    Magdalena Ratajska
    Department of Biology and Genetics, Medical University of Gdansk, 80 210 Gdansk, Debinki 1, 80 210, Poland
    Oncol Rep 19:263-8. 2008
    ..However, families with strong breast/ovarian cancer history who are negative for these common mutations should be offered a complete BRCA gene screening, including MLPA analysis...
  50. ncbi Gene copy numbers of HER family in breast cancer
    Anna Zaczek
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Debinki 7, 80 211 Gdansk, Poland
    J Cancer Res Clin Oncol 134:271-9. 2008
    ..The aim of the study was to analyze the occurrence of abnormal gene copy numbers of all HER oncogenes and to correlate these alterations to other clinicopathological variables in a consecutive series of 225 breast cancer patients...
  51. ncbi Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy
    Krystyna Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Acta Oncol 45:695-701. 2006
    ..With regard to other clinical factors, stage and tumor extension (uni- or bilateral parametrium involvement for Stage III) were the only independent determinants of prognosis...
  52. ncbi [Smoking and lung cancer]
    Ewa Jassem
    Klinika Alergologii Gdańskiego Uniwersytetu Medycznego, Gdansk
    Pneumonol Alergol Pol 77:469-73. 2009
    ..Finally, a positive impact of quitting smoking in lung cancer patients, including those who have undergone curative resection, was presented...
  53. ncbi [Adjuncts to surgery in cervical cancer]
    Krystyna Serkies
    Klinika Onkologii i Radioterapii, Akademii Medycznej w Gdansku
    Przegl Lek 62:1460-4. 2005
    ..The indications for these approaches are reviewed. Additionally, the recommendations of American Brachytherapy Society for the use of postoperative brachytherapy are presented...
  54. ncbi [The role of radiotherapy in the management of esophageal cancer]
    Krystyna Serkies
    Klinika Onkologii i Radioterapii, Akademii Medycznej w Gdansku
    Pol Merkur Lekarski 18:332-5. 2005
    ..Both brachytherapy and external beam radiotherapy are the main palliative approaches in patients with dysphagia...
  55. ncbi Chemotherapy in the primary treatment of cervical carcinoma
    Krystyna Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, ul Debinki 7, 80 211 Gdansk, Poland
    Crit Rev Oncol Hematol 54:197-208. 2005
    ..The benefit of chemotherapy applied prior to surgery remains debatable. The role of new cytotoxic and biological substances, as well as agents combating tumour hypoxia, warrants further clinical investigation...
  56. ncbi The effects of tamoxifen on the female genital tract
    Elzbieta Senkus-Konefka
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Debinki 7, Gdansk 80 211, Poland
    Cancer Treat Rev 30:291-301. 2004
    ..Further studies are warranted to develop more effective surveillance and methods decreasing the detrimental effects of tamoxifen on the female genital tract...
  57. ncbi Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation
    Elzbieta Senkus-Konefka
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Debinki 7, 80 211 Gdansk, Poland
    Cancer Treat Rev 30:671-82. 2004
    ..To minimize the risk of unfavourable outcome, the techniques and timing of both breast reconstruction and radiotherapy should be given meticulous attention...
  58. ncbi Gemcitabine and anthracyclines in breast cancer
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Semin Oncol 30:11-4. 2003
    ..Future randomized clinical trials are warranted to further elucidate the role of these regimens in breast cancer care...
  59. ncbi Salvage hemipelvis radiotherapy with fertility preservation in an adolescent with recurrent vulvar carcinoma
    Krystyna Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki Street, 80 211 Gdansk, Poland
    Gynecol Oncol 85:381-3. 2002
    ..To preserve fertility, hemi-pelvis irradiation was chosen for locoregional groin recurrence of vulvar cancer in an adolescent...
  60. ncbi Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC)
    Dorota Dworakowska
    Department of Internal Medicine, Endocrinology and Haemostatic Disorders, Medical University of Gdansk, Debinki 7 str, 80 211, Gdansk, Poland
    J Cancer Res Clin Oncol 131:479-85. 2005
    ....
  61. ncbi Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity
    Krystyna Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki Street, Gdansk 80 211, Poland
    Int J Radiat Oncol Biol Phys 60:814-21. 2004
    ..To evaluate patient compliance and acute toxicity accompanying concurrent weekly cisplatin and radiotherapy (RT) in the routine management of cervical cancer...
  62. ncbi Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer
    Dorota Dworakowska
    Department of Internal Medicine, Endocrinology and Haemostatic Disorders, Medical University of Gdansk, Poland
    Acta Oncol 44:75-9. 2005
    ..These results suggest the lack of prognostic relevance of p21WAF1/CIP1 expression (analyzed separately or jointly with p53 protein) in surgically treated NSCLC patients...
  63. ncbi The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors
    Marzena Welnicka-Jaskiewicz
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 80 211 Gdansk, Poland
    Cancer Treat Rev 29:355-61. 2003
    ..The use of HRT in breast cancer survivors is controversial, and until the results from prospective randomised trials are available, cannot be recommended in this group as a standard care...
  64. ncbi [Efficacy and feasibility evaluation in long term pamidronate treatment of bone metastases]
    Elzbieta Senkus-Konefka
    Katedra i Klinika Onkologii i Radioterapii 80 211 Gdańsk, ul Debinki 7
    Przegl Lek 60:467-70. 2003
    ..The aim of our study was to evaluate the efficacy and feasibility of long-term pamidronate treatment...
  65. ncbi Parallel-opposed fields versus four fields, and two- versus three-dimensional radiotherapy planning in thin patients with gynecological malignancies
    E Bednaruk-Młynski
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Neoplasma 55:151-7. 2008
    ....
  66. ncbi Blue-dye intraoperative sentinel lymph node mapping in early non-small cell lung cancer
    W Rzyman
    Department of Thoracic Surgery, Medical University of Gdansk, ul Debinki 7, 80 211 Gdansk, Poland
    Eur J Surg Oncol 32:462-5. 2006
    ....
  67. ncbi The feasibility study on continuous 7-day-a-week external beam irradiation in locally advanced cervical cancer: a report on acute toxicity
    K Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Debinki St. 80-211 Gdansk, Poland
    Radiother Oncol 61:197-202. 2001
    ..CONCLUSION: The studied regimen was accompanied by considerable toxicity, hindering delivery of irradiation within planned treatment time...
  68. ncbi Factors determining acute normal tissue reactions during postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases
    Barbara A Jereczek-Fossa
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Radiother Oncol 68:33-9. 2003
    ..Acute radiotherapy reactions are commonly underestimated and under-reported in the literature. Our aim was to evaluate the incidence and risk factors for acute reactions during postoperative radiotherapy in endometrial cancer patients...
  69. doi Cardiac involvement at presentation of non-small-cell lung cancer
    Katarzyna Sosinska-Mielcarek
    Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland
    J Clin Oncol 26:1010-1. 2008
  70. ncbi Modern management of symptoms and quality of life
    Jacek Jassem
    Department of Pneumonology, Medical University of Gdansk, Poland
    Curr Probl Cancer 27:69-73. 2003
  71. ncbi Role of chemotherapy in the multimodality approach of non-small cell lung cancer
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Curr Probl Cancer 27:64-8. 2003
  72. doi Combining systemic therapies with radiation in breast cancer
    Krzysztof Adamowicz
    Medical University of Gdansk, Department of Oncology and Radiotherapy, ul Debinki 7, 80 211 Gdansk, Poland
    Cancer Treat Rev 35:409-16. 2009
    ..Finally, the data on combining targeted therapies with radiation are still scarce and do not allow for meaningful conclusions...
  73. ncbi The influence of blood transfusion on survival in operated non-small cell lung cancer patients
    Witold Rzyman
    Department of Thoracic Surgery, Medical University of Gdansk, 7 Debinki Street, 80 211 Gdansk, Poland
    J Thorac Cardiovasc Surg 126:755-60. 2003
    ..The impact of autologous blood transfusion on survival has only occasionally been analyzed in cancer patients...
  74. doi Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples
    Anna Zaczek
    Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland
    Clin Biochem 43:891-8. 2010
    ..The objective of this study was to develop a new real time PCR-based method for quantitative detection of topoisomerase II alpha (TOP2A) aberrations and to evaluate its clinical utility in breast cancer...
  75. doi The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Eur J Cancer 45:2749-58. 2009
    ..We performed a systematic review of controlled clinical trials of the cytotoxic agents currently used for this population in Europe: capecitabine, gemcitabine, vinorelbine, docetaxel, paclitaxel and paclitaxel protein-bound particles...
  76. doi Exemestane: an alternative treatment option in early breast cancer. Foreward
    Jacek Jassem
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Anticancer Drugs 19:S1. 2008
  77. ncbi Conservative treatment for carcinoma of the anus--a report of 35 patients
    K Serkies
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 80 211 Gdansk, Poland
    Neoplasma 50:152-8. 2003
    ..However, the risk of local failure is relatively high in patients with large primary tumors. Combined chemo-radiation is associated with relatively high rate of acute toxicity...
  78. ncbi Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report
    Ewa J Majdak
    Department of Gynecology, Medical University of Gdansk, ul Kliniczna 1A, Gdnask, Poland
    Eur J Cancer 41:143-50. 2005
    ..Except for infertility and hyperthyroidism, unclassified variant-linked ovarian tumours share features with sporadic tumours rather than with BRCA1 pathogenic mutations...
  79. ncbi Relationship between acute and late normal tissue injury after postoperative radiotherapy in endometrial cancer
    Barbara A Jereczek-Fossa
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
    Int J Radiat Oncol Biol Phys 52:476-82. 2002
    ..To evaluate the relationship between acute and late normal tissue reactions in 317 consecutive endometrial cancer patients treated with surgery and adjuvant radiotherapy (RT)...
  80. doi Combined treatment with cytoprotective agents and radiotherapy
    Piotr Winczura
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland
    Cancer Treat Rev 36:268-75. 2010
    ..The use of erythropoetins in combination with radiotherapy should generally be discouraged, whereas the safe and effective application of other agents warrants further investigations...
  81. ncbi Cardiovascular effects of breast cancer radiotherapy
    Elzbieta Senkus-Konefka
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Debinki 7, 80 211 Gdansk, Poland
    Cancer Treat Rev 33:578-93. 2007
    ..Additionally, non-cardiac radiation-related vascular morbidity and mortality in breast cancer patients are addressed...
  82. ncbi Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer
    Magdalena Chmara
    Department of Biology and Genetics, Medical University of Gdansk, Gdansk, Poland
    Anticancer Res 24:4259-63. 2004
    ..Loss of heterozygosity (LOH) of selected regions at chromosomes 3p and 17p in non-small cell lung cancer (NSCLC) and the association of these abnormalities with major clinical parameters and prognosis were studied...
  83. ncbi Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma
    Ewa Joanna Majdak
    Department of Gynecology, Medical University of Gdansk, Poland
    Cancer 104:1004-12. 2005
    ..Our aim was to determine factors influencing the risk of recurrence and death in ovarian carcinoma patients with BRCA pathogenic and unclassified variant mutations...
  84. doi Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    Tomasz Burzykowski
    Hasselt University, Center for Statistics, Agoralaan, Bldg D, 3590 Diepenbeek, Belgium
    J Clin Oncol 26:1987-92. 2008
    ....
  85. ncbi Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    Jean Yves Douillard
    Centre Rene Gauducheau, Nantes, France
    Lancet Oncol 7:719-27. 2006
    ..We aimed to compare the effect of adjuvant vinorelbine plus cisplatin versus observation on survival in patients with completely resected NSCLC...
  86. doi Exacerbation of diabetes related to exemestane treatment
    Elzbieta Senkus-Konefka
    Acta Oncol 47:1167-9. 2008
  87. ncbi A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    R Charles Coombes
    Department of Cancer Medicine, Imperial College and Charing Cross Hospital, London, United Kingdom
    N Engl J Med 350:1081-92. 2004
    ..Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse...
  88. ncbi Time without symptoms and toxicity (TWIST) analysis of adjuvant radiation therapy for endometrial cancer
    Barbara A Jereczek-Fossa
    Department of Radiation Oncology, European Institute of Oncology, 435 Via Ripamonti, 20141 Milan, Italy
    Radiother Oncol 72:175-81. 2004
    ..The aim of our study was to evaluate time without tumor symptoms and toxicity (TWIST) in a consecutive series of 317 endometrial cancer patients administered postoperative irradiation...
  89. ncbi [Late recurrence of malignant tumours 20 years after diagnosis and treatment]
    Zygmunt Chodorowski
    Katedra i Klinika Chorob Wewnetrznych, Geriatrii i Toksykologii Klinicznej, Akademii Medycznej w Gdansku
    Przegl Lek 64:372-3. 2007
    ..The histopathological examination results of primary and recurrent tumours were identical. Six patients died at the age from 40 to 89 (mean 66.8) years. The survival of patients after recurrence was from 4 to 11 (mean 7.3) months...
  90. ncbi [P53 and P16 gene mutations in non-small cell lung cancer]
    Ewa Jassem
    Klinika Chorób Płuc i Gruźlicy, AM w Gdańsku
    Pneumonol Alergol Pol 70:64-70. 2002
    ..These results indicate that p53 and p16 gene mutations tend to occur together in NSCLC, however these alterations seem not to have noteworthy clinical and prognostic significance...
  91. ncbi Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial
    Thomas Brodowicz
    Medical University Hospital, Vienna, Austria
    Lung Cancer 52:155-63. 2006
    ....
  92. ncbi Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
    Natasha B Leighl
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
    J Clin Oncol 23:2831-9. 2005
    ..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs...
  93. ncbi Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  94. ncbi Epoetin beta therapy in patients with solid tumours
    Paolo Pronzato
    Medical Oncology, S Andrea Hospital, La Spezia, Italy
    Crit Rev Oncol Hematol 58:46-52. 2006
    ..Therefore, epoetin beta offers an effective, safe and convenient therapy for the management of anaemia in patients with cancer...
  95. doi Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
    Martine J Piccart-Gebhart
    Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    J Clin Oncol 26:1980-6. 2008
    ..This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival...
  96. doi Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I
    Rodryg Ramlau
    Lung Disease Centre, Oncology Department, ul Szamarzewskiego, Poznan, Poland
    J Clin Oncol 26:1886-92. 2008
    ..This study evaluated whether the combination of the synthetic rexinoid bexarotene with first-line cisplatin/vinorelbine therapy provides additional survival benefit in patients with advanced non-small-cell lung cancer (NSCLC)...
  97. ncbi Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer
    Pieter E Postmus
    Department of Pulmonary Diseases, Vrije Universiteit Medical Cetner, Amsterdam, Netherlands
    Lung Cancer 42:S3-6. 2003
  98. pmc BRCA1: a novel prognostic factor in resected non-small-cell lung cancer
    Rafael Rosell
    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
    PLoS ONE 2:e1129. 2007
    ....
  99. ncbi Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
    ..The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial...
  100. ncbi [Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group]
    Maciej Krzakowski
    Centrum Onkologii Instytut w Warszawie
    Pneumonol Alergol Pol 75:88-94. 2007
    ..Extensive-stage disease should be managed by multi-agent chemotherapy alone. Long-term survivors should undergo careful monitoring for development of a second primary tumour...
  101. doi Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
    Filippo De Marinis
    Forlanini Hospital, Rome, Italy
    J Thorac Oncol 3:30-6. 2008
    ..The low response rates and minimal survival gains observed in second-line studies underscore the need to assess treatment efficacy with symptomatic end points...